Oppenheimer resumed coverage on Cue Biopharma with a new price target
$CUE
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer resumed coverage of Cue Biopharma with a rating of Outperform and set a new price target of $10.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/13/2024 | $6.00 | Buy | Jefferies |
| 6/26/2023 | $10.00 | Outperform | Oppenheimer |
| 11/21/2022 | $7.00 | Overweight | Piper Sandler |
| 1/13/2022 | $20.00 | Buy | H.C. Wainwright |
| 1/3/2022 | $28.00 | Buy | Craig Hallum |